Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 |
| clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04043676 | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | unknown | Phase 2 | 40 | Fundación Teófilo Hernando, SpainOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT03062436 | To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission | unknown | N/A | 27 | Command Hospital, IndiaOTHER_GOV | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00780104 | Sirolimus in Combination With MEC in High Risk Myeloid Leukemias(UPCC 02407) | completed | Phase 1 | 16 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00632255 | Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment | completed | — | 88 | Imperial College LondonOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02253277 | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients(CoRNea) | completed | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | terminated | Phase 2 | 32 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03075969 | Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia | unknown | — | 337 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 9 | Mar 21, 2019 | clinicaltrials |
| NCT03348033 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | terminated | Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02730195 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia | terminated | Phase 2 | 9 | Emory UniversityOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT01933906 | Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response | completed | Phase 1 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT01490853 | Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy | completed | — | 116 | Università degli Studi di BresciaOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02709083 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT01866553 | Nilotinib Plus Pegylated Interferon-α2b in CML | terminated | Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 5 | Oct 12, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00061581 | Experimental Bone Marrow Transplant Protocol | completed | Phase 2 | 14 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01490775 | Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy | terminated | N/A | 27 | Rex Cancer Center, Raleigh, NCOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT01490983 | Telemonitoring Study - for Chronic Myeloid Leukemia (CML) | terminated | N/A | 14 | Rex Cancer Center, Raleigh, NCOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT03625583 | The Hong Kong CML Registry | unknown | — | 200 | The University of Hong KongOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01535391 | Nilotinib in PH+, BCR-, ABL+ CML Patients(CML0811) | completed | Phase 3 | 109 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT02164903 | LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients(QoL-CML0713) | unknown | — | 323 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 4 | Aug 6, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01761695 | Chronic Myelod Leukemia Registry at Asan Medical Center | terminated | — | 100 | Asan Medical CenterOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00898079 | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | completed | — | 2,545 | Children's Oncology GroupNETWORK | 6 | Jul 19, 2018 | clinicaltrials |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | completed | Phase 2 | 61 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03573596 | Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment(DASTOP2) | unknown | Phase 2 | 134 | Amsterdam UMC, location VUmcOTHER | 7 | Jun 29, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | terminated | Phase 4 | 55 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02895542 | Preparatory Work to Assess Adherence to Oral Chemotherapy | completed | — | 86 | Wake Forest University Health SciencesOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT03515018 | Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients(HU) | unknown | Phase 3 | 60 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | terminated | Phase 2 | 9 | Sherif S. FaragOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02204644 | The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML | completed | Phase 3 | 400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT01592136 | Expanded Access Program of Ponatinib | approved for marketing | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 24, 2019source: clinicaltrials